| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.04 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.04 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.04 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.04 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.061 | 0.04 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |